Incyte Corp (INCY)

Add to Watchlists
Create an Alert
Quickflows
108.72 +0.93  +0.86% NASDAQ Jul 7, 16:58 Delayed 2m USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All INCY News

News

View All Events

Events

Date Type Description
07/30/2020 08:00 EDT Misc Incyte Corp Second Quarter Earnings Conference Call in 2020
07/30/2020 Earnings Incyte Corp Second Quarter Earnings in 2020 Release
05/26/2020 13:00 EDT Misc Incyte Corp Annual General Meeting for 2019
05/05/2020 08:00 EDT Misc Incyte Corp First Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Incyte Corp First Quarter Earnings Result for 2020
02/13/2020 08:00 EST Misc Incyte Corp Fourth Quarter Earnings Conference Call for 2019
02/13/2020 07:00 EST Earnings Incyte Corp Fourth Quarter Earnings Results for 2019
02/13/2020 Misc Incyte Corp Annual Report for 2019
10/29/2019 08:00 EDT Misc Incyte Corp Third Quarter Earnings Conference Call for 2019
10/29/2019 07:00 EDT Earnings Incyte Corp Third Quarter Earnings Results for 2019
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 2.229B
Total Expenses (TTM) 2.546B
Net Income (TTM) -376.05M

Balance Sheet View Statement

Total Assets (Quarterly) 2.752B
Total Liabilities (Quarterly) 814.70M
Shareholders Equity (Quarterly) 1.938B

Cash Flow Statement View Statement

Cash from Operations (TTM) -128.42M
Cash from Investing (TTM) -171.45M
Cash from Financing (TTM) 43.72M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.incyte.com
  • Investor Relations URL: http://www.incyte.com/ir/investor-overview.aspx
  • HQ State/Province: Delaware
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Jul. 30, 2020
  • Last Earnings Release: May. 05, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma) and Tabrecta (lung cancer). Incyte's pipeline includes a broad array of oncology and dermatology programs.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 108.72
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.18%
ARKG ARK Genomic Revolution ETF 2.50%
IBB iShares Nasdaq Biotechnology ETF 2.44%
VGHCX Vanguard Health Care Inv 1.86%
VCHSX VALIC Company I Health Sciences 1.70%
RPG Invesco S&P 500® Pure Growth ETF 1.69%
IMORX Voya MidCap Opportunities R 1.68%
IMOPX Voya MidCap Opportunities Port S2 1.67%
THISX T. Rowe Price Health Sciences I 1.47%
XBI SPDR® S&P Biotech ETF 1.13%
FMEIX Fidelity® Mid Cap Enhanced Index 0.76%
RSP Invesco S&P 500® Equal Weight ETF 0.23%

Comparables

Edit
GILD Gilead Sciences Inc
LLY Eli Lilly and Co
REGN Regeneron Pharmaceuticals Inc
MRNA Moderna Inc
ALXN Alexion Pharmaceuticals Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.